Gyre Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Jan '26 Jan 21, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	754	1,038	1,967	-
Market Cap Growth	-26.75%	-47.22%	-	-
Enterprise Value	696	1,050	1,946	-
Last Close Price	8.30	12.10	25.69	-
PE Ratio	212.05	85.93	-	-
PS Ratio	6.76	9.82	17.34	-
PB Ratio	7.40	10.55	25.07	-
P/TBV Ratio	7.77	16.85	-	-
P/FCF Ratio	260.49	-	113.23	-
P/OCF Ratio	194.58	-	75.99	-
EV/Sales Ratio	6.48	9.93	17.15	-
EV/EBITDA Ratio	48.44	58.96	95.72	-
EV/EBIT Ratio	57.80	64.73	101.27	-
EV/FCF Ratio	240.16	-	111.99	-
Debt / Equity Ratio	0.01	0.02	0.01	0.01
Debt / EBITDA Ratio	0.08	0.09	0.02	0.06
Debt / FCF Ratio	0.40	-	0.02	0.11
Asset Turnover	0.75	0.87	1.13	-
Inventory Turnover	0.64	0.73	0.89	-
Quick Ratio	5.41	2.64	2.49	3.33
Current Ratio	6.20	3.32	2.85	4.06
Return on Equity (ROE)	10.02%	20.24%	-113.45%	-
Return on Assets (ROA)	5.29%	8.38%	11.93%	-
Return on Invested Capital (ROIC)	6.30%	11.34%	15.83%	-
Return on Capital Employed (ROCE)	8.40%	15.30%	19.90%	12.70%
Earnings Yield	0.88%	1.16%	-4.72%	-
FCF Yield	0.38%	-0.57%	0.88%	-
Buyback Yield / Dilution	-24.46%	-55.39%	13.02%	-

Updated Nov 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q